{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T09:44:22Z","timestamp":1751449462177},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"am","delay-in-days":362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.encep.2023.01.011","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T11:54:58Z","timestamp":1680263698000},"page":"137-142","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and tolerance of combination of monoamine oxidase inhibitors and direct dopamine agonists in adults and older adults with highly resistant depression"],"prefix":"10.1016","volume":"50","author":[{"given":"L.C.","family":"Dormegny-Jeanjean","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.A.E.","family":"Mainberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"de Crespin de Billy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Obrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Danila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Erb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.M.","family":"Arcay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Weibel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tomsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Bertschy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Duval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.R.","family":"Foucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.encep.2023.01.011_bib0230","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/ijnp\/pyx056","article-title":"Dopamine system dysregulation in major depressive disorders","volume":"20","author":"Belujon","year":"2017","journal-title":"Int J Neuropsychopharmacol."},{"key":"10.1016\/j.encep.2023.01.011_bib0235","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41593-018-0152-y","article-title":"What does dopamine mean?","volume":"21","author":"Berke","year":"2018","journal-title":"Nat Neurosci."},{"key":"10.1016\/j.encep.2023.01.011_bib0240","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/0963721412474460","article-title":"Parsing anhedonia: translational models of reward-processing deficits in psychopathology","volume":"22","author":"Treadway","year":"2013","journal-title":"Curr Dir Psychol Sci."},{"key":"10.1016\/j.encep.2023.01.011_bib0245","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.encep.2023.01.011_bib0250","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jad.2017.07.022","article-title":"Apathy in early and late-life depression","volume":"223","author":"Groeneweg-Koolhoven","year":"2017","journal-title":"J Affect Disord."},{"key":"10.1016\/j.encep.2023.01.011_bib0255","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12888-020-02514-2","article-title":"How well do elderly patients with major depressive disorder respond to antidepressants: a systematic review and single-group meta-analysis","volume":"20","author":"Gutsmiedl","year":"2020","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.encep.2023.01.011_bib0260","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1176\/ajp.148.7.910","article-title":"Tranylcypromine versus imipramine in anergic bipolar depression","volume":"148","author":"Himmelhoch","year":"1991","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2023.01.011_bib0265","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1176\/ajp.149.2.195","article-title":"Treatment of imipramine-resistant recurrent depression. IV: a double-blind crossover study of tranylcypromine for anergic bipolar depression","volume":"149","author":"Thase","year":"1992","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.encep.2023.01.011_bib0270","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/00005053-198210000-00007","article-title":"A double-blind study of tranylcypromine treatment of major anergic depression","volume":"170","author":"Himmelhoch","year":"1982","journal-title":"J Nerv Ment Dis."},{"key":"10.1016\/j.encep.2023.01.011_bib0275","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/phar.1576","article-title":"Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression","volume":"35","author":"Thomas","year":"2015","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.encep.2023.01.011_bib0280","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/164_2018_133","article-title":"Tricyclic antidepressants and monoamine oxidase inhibitors: are they too old for a new look?","volume":"250","author":"Chockalingam","year":"2019","journal-title":"Handb Exp Pharmacol."},{"key":"10.1016\/j.encep.2023.01.011_bib0285","first-page":"1","article-title":"The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression","author":"Van den Eynde","year":"2022","journal-title":"CNS Spectr"},{"key":"10.1016\/j.encep.2023.01.011_bib0290","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1503\/jpn.110038","article-title":"Long-term administration of the dopamine D3\/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain","volume":"37","author":"Chernoloz","year":"2012","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.encep.2023.01.011_bib0295","doi-asserted-by":"crossref","first-page":"105434","DOI":"10.1016\/j.phrs.2021.105434","article-title":"Prolonged dopamine D(3) receptor stimulation promotes dopamine transporter ubiquitination and degradation through a PKC-dependent mechanism","volume":"165","author":"Luis-Ravelo","year":"2021","journal-title":"Pharmacol Res."},{"key":"10.1016\/j.encep.2023.01.011_bib0300","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.clinthera.2006.08.004","article-title":"A review of the receptor-binding and pharmacokinetic properties of dopamine agonists","volume":"28","author":"Kvernmo","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.encep.2023.01.011_bib0305","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40263-017-0450-z","article-title":"Dopaminergic therapies for non-motor symptoms in Parkinson's disease","volume":"31","author":"Schaeffer","year":"2017","journal-title":"CNS Drugs."},{"key":"10.1016\/j.encep.2023.01.011_bib0310","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/acps.13055","article-title":"Pramipexole in the treatment of unipolar and bipolar depression. A systematic review and meta-analysis","volume":"140","author":"Tundo","year":"2019","journal-title":"Acta Psychiatr Scand."},{"key":"10.1016\/j.encep.2023.01.011_bib0315","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1176\/appi.ajp.2015.15060788","article-title":"Clinical experience with high-dosage pramipexole in patients with treatment-resistant depressive episodes in unipolar and bipolar depression","volume":"173","author":"Fawcett","year":"2016","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.encep.2023.01.011_bib0320","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/YIC.0b013e3283639015","article-title":"Assessing efficacy\/effectiveness and safety\/tolerability profiles of adjunctive pramipexole in bipolar depression: acute versus long-term data","volume":"28","author":"Dell\u2019Osso","year":"2013","journal-title":"Int Clin Psychopharmacol."},{"key":"10.1016\/j.encep.2023.01.011_bib0325","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jad.2013.02.003","article-title":"Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study","volume":"149","author":"Franco-Chaves","year":"2013","journal-title":"J Affect Disord."},{"key":"10.1016\/j.encep.2023.01.011_bib0330","doi-asserted-by":"crossref","first-page":"372474","DOI":"10.1100\/2012\/372474","article-title":"The efficacy of pramipexole, a dopamine receptor agonist, as an adjunctive treatment in treatment-resistant depression: an open-label trial","volume":"2012","author":"Hori","year":"2012","journal-title":"Sci World J"},{"key":"10.1016\/j.encep.2023.01.011_bib0335","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.biopsych.2004.03.013","article-title":"Pramipexole for bipolar II depression: a placebo-controlled proof of concept study","volume":"56","author":"Zarate","year":"2004","journal-title":"Biol Psychiatry."},{"key":"10.1016\/j.encep.2023.01.011_bib0340","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1034\/j.1399-5618.2002.01171.x","article-title":"Pramipexole in treatment-resistant depression: a 16-week naturalistic study","volume":"4","author":"Lattanzi","year":"2002","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.encep.2023.01.011_bib0345","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1055\/s-2001-15872","article-title":"Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series","volume":"34","author":"Perugi","year":"2001","journal-title":"Pharmacopsychiatry."},{"key":"10.1016\/j.encep.2023.01.011_bib0350","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.26941","article-title":"A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease","volume":"32","author":"Olanow","year":"2017","journal-title":"Mov Disord."},{"key":"10.1016\/j.encep.2023.01.011_bib0355","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/JCP.0000000000001139","article-title":"Pramipexole and selegiline combination therapy in a case of treatment-resistant depression","volume":"39","author":"Moirand","year":"2019","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.encep.2023.01.011_bib0360","first-page":"37","article-title":"Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology","volume":"89","author":"Borovac","year":"2016","journal-title":"Yale J Biol Med."},{"key":"10.1016\/j.encep.2023.01.011_bib0365","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/1039856219839476","article-title":"Dopamine dysregulation syndrome in non-Parkinson's disease patients: a systematic review","volume":"27","author":"Cartoon","year":"2019","journal-title":"Australas Psychiatry"},{"key":"10.1016\/j.encep.2023.01.011_bib0370","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","article-title":"Dopamine agonists and impulse control disorders: a complex association","volume":"41","author":"Grall-Bronnec","year":"2018","journal-title":"Drug Safety."},{"key":"10.1016\/j.encep.2023.01.011_bib0375","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/00023210-200923020-00005","article-title":"Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management","volume":"23","author":"O'Sullivan","year":"2009","journal-title":"CNS Drugs."},{"key":"10.1016\/j.encep.2023.01.011_bib0380","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/WNF.0b013e31826e6e6d","article-title":"Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease","volume":"35","author":"Perez-Lloret","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.encep.2023.01.011_bib0385","series-title":"The Maudsley prescribing guidelines in psychiatry","author":"Taylor","year":"2015"},{"key":"10.1016\/j.encep.2023.01.011_bib0390","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","article-title":"The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression","volume":"54","author":"Rush","year":"2003","journal-title":"Biol Psychiatry."},{"key":"10.1016\/j.encep.2023.01.011_bib0395","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/138945006775515392","article-title":"Potentiation of antidepressant-like activity with lithium: mechanism involved","volume":"7","author":"Chenu","year":"2006","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.encep.2023.01.011_bib0400","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1755-5949.2011.00260.x","article-title":"Lithium: still a major option in the management of bipolar disorder","volume":"18","author":"Licht","year":"2012","journal-title":"CNS Neurosci Ther"},{"issue":"Suppl 13","key":"10.1016\/j.encep.2023.01.011_bib0405","first-page":"23","article-title":"When at first you don\u2019t succeed: sequential strategies for antidepressant nonresponders","volume":"58","author":"Thase","year":"1997","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.encep.2023.01.011_bib0410","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","article-title":"Research criteria for the diagnosis of prodromal dementia with Lewy bodies","volume":"94","author":"McKeith","year":"2020","journal-title":"Neurology."},{"key":"10.1016\/j.encep.2023.01.011_bib0415","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1176\/ajp.2006.163.9.1531","article-title":"Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report","volume":"163","author":"McGrath","year":"2006","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.encep.2023.01.011_bib0420","doi-asserted-by":"crossref","first-page":"110425","DOI":"10.1016\/j.pnpbp.2021.110425","article-title":"Efficacy and safety of 24-week pramipexole augmentation in patients with treatment resistant depression. A retrospective cohort study","volume":"112","author":"Tundo","year":"2022","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.encep.2023.01.011_bib0425","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1586\/14737175.2016.1158103","article-title":"Treatment of impulse control disorders in Parkinson's disease: practical considerations and future directions","volume":"16","author":"Ramirez-Zamora","year":"2016","journal-title":"Exp Rev Neurother"},{"key":"10.1016\/j.encep.2023.01.011_bib0430","first-page":"1089","article-title":"Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy","volume":"23","author":"Hamidianjahromi","year":"2022","journal-title":"Rev Endocr Metab Disord."},{"key":"10.1016\/j.encep.2023.01.011_bib0435","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/WNF.0b013e31820d6699","article-title":"The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome","volume":"34","author":"Dang","year":"2011","journal-title":"Clin Neuropharmacol."},{"key":"10.1016\/j.encep.2023.01.011_bib0440","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1471-2377-11-117","article-title":"Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome","volume":"11","author":"Voon","year":"2011","journal-title":"BMC Neurol."},{"key":"10.1016\/j.encep.2023.01.011_bib0445","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mp.2017.16","article-title":"The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment","volume":"22","author":"Ashok","year":"2017","journal-title":"Mol Psychiatry."},{"key":"10.1016\/j.encep.2023.01.011_bib0450","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1038\/npp.2014.170","article-title":"Reduced dopamine transporter functioning induces high-reward risk-preference consistent with bipolar disorder","volume":"39","author":"van Enkhuizen","year":"2014","journal-title":"Neuropsychopharmacology."}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700623000246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700623000246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T16:50:40Z","timestamp":1711731040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0013700623000246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0013700623000246"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2023.01.011","relation":{},"ISSN":["0013-7006"],"issn-type":[{"value":"0013-7006","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerance of combination of monoamine oxidase inhibitors and direct dopamine agonists in adults and older adults with highly resistant depression","name":"articletitle","label":"Article Title"},{"value":"L'Enc\u00e9phale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.encep.2023.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 L'Enc\u00e9phale, Paris.","name":"copyright","label":"Copyright"}]}}